Operational since 2005, Supernus Pharmaceuticals is a specialty pharmaceutical company that develops products and technologies for the treatment of central nervous system disorders. The company offers the ProScreen, ProPhile and OptiScreen technologies for lead selection and formulation optimization. It also provides oral controlled release solutions under the Microtrol, Solutrol and EnSoTrol brands. Supernus Pharmaceuticals' technology platform, Avert, reduces the abuse potential of formulations that deliver scheduled substances. In addition, it is involved in the clinical-stage development of drug candidates that can be used for the treatment of epilepsy, depression, anxiety, conduct disorder and Parkinson s disease. The company works in partnership with Afecta Pharmaceuticals and Rune Healthcare Limited.